5354 Store at -20C

EGF Receptor (L858R Mutant Specific) (43B2) Rabbit mAb (Biotinylated)



Orders: 877-616-CELL (2355)

orders@cell signal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Reactivity: H	Sensitivity: Endogenous	MW (kDa): 175	Source/Isotype: Rabbit IgG	UniProt ID: #P00533	Entrez-Gene Id 1956
Ap	plication			Dilution	
We	estern Blotting			1:1000	
	Supplied in 136 mM NaCl, 2.6 mM KCl, 12 mM sodium phosphate (pH 7.4) dibasic, 2 mg/ml BSA, and 50% glycerol. Store at –20°C. Do not aliquot the antibodies.				
mut	EGFR (L858R Mutant Specific) (43B2) Rabbit mAb (Biotinylated) detects endogenous levels of EGFR mutant L858R protein. The antibody may cross-react with wildtype EGFR and other HER family members when highly over-expressed. Careful titration of this antibody may be required to obtain optimal specificity.				
	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to L858R mutant sequence of human EGF receptor.				
anti	This Cell Signaling Technology antibody is conjugated to biotin under optimal conditions. The biotinylated antibody is expected to exhibit the same species cross-reactivity as the unconjugated EGFR (L858R Mutant Specific) (43B2) Rabbit mAb #3197.				
	175				
the don inhi mut exo	The epidermal growth factor (EGF) receptor is a 170 kDa transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Research studies have shown that somatic mutations in the tyrosine kinase domain of EGF receptor (EGFR) are present in a subset of lung adenocarcinomas that respond to EGFR inhibitors, such as gefitinib and erlotinib (1-3). Two types of mutations account for approximately 90% of mutated cases: a specific point mutation, L858R, that occurs in exon 21 and short in-frame deletions in exon 19 (4,5). The most frequent exon 19 deletion is E746-A750, accounting for 90% of lesions at this site, although some rare variants occur.				
2. P 3. H 4. K	 Lynch, T.J. et al. (2004) N Engl J Med 350, 2129-39. Pao, W. et al. (2004) Proc Natl Acad Sci USA 101, 13306-11. Haber, D.A. et al. (2005) Cold Spring Harb Symp Quant Biol 70, 419-26. Kosaka, T. et al. (2004) Cancer Res 64, 8919-23. Riely, G.J. et al. (2006) Clin Cancer Res 12, 7232-41. 				
	Ap We Sup 50% Vity EGI mut whe In Mor mut This anti Mut The don inhil mut exo alth 2. P 3. H 4. K	Application Western Blotting Supplied in 136 mM Na 50% glycerol. Store at - vity EGFR (L858R Mutant S mutant L858R protein. when highly over-express mutant sequence of human that sequ	Application Western Blotting Supplied in 136 mM NaCl, 2.6 mM KCl, 50% glycerol. Store at –20°C. Do not alid Vity EGFR (L858R Mutant Specific) (43B2) F mutant L858R protein. The antibody may when highly over-expressed. Careful titra Monoclonal antibody is produced by imm mutant sequence of human EGF receptor This Cell Signaling Technology antibody antibody is expected to exhibit the same Mutant Specific) (43B2) Rabbit mAb #31 The epidermal growth factor (EGF) receptor (EGFR) are preinhibitors, such as gefitinib and erlotinib mutated cases: a specific point mutation exon 19 (4,5). The most frequent exon 1 although some rare variants occur. PINCES 1. Lynch, T.J. et al. (2004) N Engl J Med 2. Pao, W. et al. (2004) Proc Natl Acad S 3. Haber, D.A. et al. (2005) Cold Spring M 4. Kosaka, T. et al. (2004) Cancer Res 6.	Application Western Blotting Supplied in 136 mM NaCl, 2.6 mM KCl, 12 mM sodium phospha 50% glycerol. Store at –20°C. Do not aliquot the antibodies. Vity EGFR (L858R Mutant Specific) (43B2) Rabbit mAb (Biotinylated mutant L858R protein. The antibody may cross-react with wildty, when highly over-expressed. Careful titration of this antibody may mutant sequence of human EGF receptor. This Cell Signaling Technology antibody is conjugated to biotin unantibody is expected to exhibit the same species cross-reactivity Mutant Specific) (43B2) Rabbit mAb #3197. The epidermal growth factor (EGF) receptor is a 170 kDa transmathe HER/ErbB protein family. Research studies have shown that domain of EGF receptor (EGFR) are present in a subset of lung inhibitors, such as gefitinib and erlotinib (1-3). Two types of mutamutated cases: a specific point mutation, L858R, that occurs in exon 19 (4,5). The most frequent exon 19 deletion is E746-A750 although some rare variants occur. PINCES 1. Lynch, T.J. et al. (2004) N Engl J Med 350, 2129-39. 2. Pao, W. et al. (2004) Proc Natl Acad Sci USA 101, 13306-11. 3. Haber, D.A. et al. (2005) Cold Spring Harb Symp Quant Biol 74. Kosaka, T. et al. (2004) Cancer Res 64, 8919-23.	Application Western Blotting Supplied in 136 mM NaCl, 2.6 mM KCl, 12 mM sodium phosphate (pH 7.4) dibasic, 2 50% glycerol. Store at -20°C. Do not aliquot the antibodies. Vity EGFR (L858R Mutant Specific) (43B2) Rabbit mAb (Biotinylated) detects endogenous mutant L858R protein. The antibody may cross-react with wildtype EGFR and other H when highly over-expressed. Careful titration of this antibody may be required to obtai Monoclonal antibody is produced by immunizing animals with a synthetic peptide corn mutant sequence of human EGF receptor. This Cell Signaling Technology antibody is conjugated to biotin under optimal condition antibody is expected to exhibit the same species cross-reactivity as the unconjugated Mutant Specific) (43B2) Rabbit mAb #3197. 175 The epidermal growth factor (EGF) receptor is a 170 kDa transmembrane tyrosine kin the HER/ErbB protein family. Research studies have shown that somatic mutations in domain of EGF receptor (EGFR) are present in a subset of lung adenocarcinomas the inhibitors, such as gefitinib and erlotinib (1-3). Two types of mutations account for app mutated cases: a specific point mutation, L858R, that occurs in exon 21 and short infexon 19 (4,5). The most frequent exon 19 deletion is E746-A750, accounting for 90% although some rare variants occur. 1. Lynch, T.J. et al. (2004) N Engl J Med 350, 2129-39. 2. Pao, W. et al. (2004) Proc Natl Acad Sci USA 101, 13306-11. 3. Haber, D.A. et al. (2005) Cold Spring Harb Symp Quant Biol 70, 419-26. 4. Kosaka, T. et al. (2004) Cancer Res 64, 8919-23.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key WB: Western Blotting

Cross-Reactivity Key

H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster

X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse

GP: Guinea Pig Rab: rabbit All: all species expected

Trademarks and

Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more

information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.